VNX-101

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameVNX-101
Drug Alias NameVNX-101
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsB-lymphocyte antigen CD19 modulators
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVironexis Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVironexis Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A